ArticleFrontiers in nutrition2025
Trends and projections of the disease burden of vitamin A deficiency in China from 1990 to 2021.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The current systematic research on the disease burden of Vitamin A deficiency in China is limited. To analyze the trends in the disease burden of Vitamin A Deficiency (VAD) in China from 1990 to 2021 and predict future trends from 2022 to 2050, providing a scientific basis for the prevention of VAD in China. Methods: Based on the Global Burden of Disease (GBD) data, we extracted incidence, prevalence, and disability-adjusted life years (DALYs) for VAD in China from 1990 to 2021. The Joinpoint regression model was used to analyze temporal trends, calculating the estimated annual percentage change (EAPC) and its 95% confidence interval (CI). The Bayesian Age-Period-Cohort (BAPC) model was employed to integrate age, period, and cohort effects for predicting China's VAD disease burden from 2022 to 2050. Results: From 1990 to 2021, the Age-Standardized Incidence Rate (ASIR), Age-Standardized Prevalence Rate (ASPR), and Age-Standardized Disability-Adjusted Life Year Rate (ASR-DALYs) of VAD in China showed a significant downward trend, with Estimated Annual Percentage Change (EAPC) values of -5.31 (95% CI: -5.65 to -4.96), -5.31 (95% CI: -5.66 to -4.96), and -3.86 (95% CI, -4.84 to -2.86), respectively. The disease burden was higher in females than in males and higher in children than in adults. According to the BAPC model, the ASR-DALYs of VAD in China are expected to stabilize from 2022 to 2050, with a gradual decline from 3. 17/100,000 in 2022 to 2.70/100,000 in 2050. The ASIR and ASPR are projected to continue declining, with ASIR decreasing from 1,838. 15/100,000 in 2022 to 269.57/100,000 in 2050 and ASPR decreasing from 1,835.08/100,000 in 2022 to 267.89/100,000 in 2050. Conclusion: While China's VAD burden has shown sustained reduction, continued attention is needed for children and women to address the "hidden hunger" of micronutrient deficiencies. Future efforts should strengthen nutritional interventions and health education to further mitigate the disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.